Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current clinical management of CIDP with immunoglobulins in France: An expert opinion.
Cintas P, Bouhour F, Cauquil C, Masingue M, Tard C, Sacconi S, Delmont E, Choumert A, Chanson JB, Michaud M, Solé G, Cassereau J, Noury JB, Nicolas G, Bellance R, Péréon Y, Camdessanché JP, Magy L, Attarian S; French Neuromuscular diseases network (Filnemus). Cintas P, et al. Among authors: delmont e. Rev Neurol (Paris). 2023 Oct;179(8):914-922. doi: 10.1016/j.neurol.2023.03.010. Epub 2023 Apr 3. Rev Neurol (Paris). 2023. PMID: 37019741 Free article.
The autoimmune vulnerability of the node of Ranvier.
Querol L, Delmont E, Lleixà C. Querol L, et al. Among authors: delmont e. J Peripher Nerv Syst. 2023 Jul;28 Suppl 3:S12-S22. doi: 10.1111/jns.12570. J Peripher Nerv Syst. 2023. PMID: 37272737 Review.
Substitutions at residue 211 in the prion protein drive a switch between CJD and GSS syndrome, a new mechanism governing inherited neurodegenerative disorders.
Peoc'h K, Levavasseur E, Delmont E, De Simone A, Laffont-Proust I, Privat N, Chebaro Y, Chapuis C, Bedoucha P, Brandel JP, Laquerriere A, Kemeny JL, Hauw JJ, Borg M, Rezaei H, Derreumaux P, Laplanche JL, Haïk S. Peoc'h K, et al. Among authors: delmont e. Hum Mol Genet. 2012 Dec 15;21(26):5417-28. doi: 10.1093/hmg/dds377. Epub 2012 Sep 10. Hum Mol Genet. 2012. PMID: 22965875
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
136 results